Educational Resources and Programs

Register for a virtual meeting

Link:Prevalence and antithrombotic management of atrial fibrillation in hospitalised patients, Dana Berti, et al.

The objective of this study was to determine the prevalence of atrial fibrillation (AF) in a tertiary care centre, to describe the comorbidity profile of hospitalised patients with AF, and to evaluate the appropriateness of their maintenance antithrombotic management.

Link:Risk of Stroke in Non-Rheumatic Atrial Fibrillation, K.M.Flegel, et al.

Estimates of the risk of stroke for men with non-rheumatic atrial fibrillation were obtained from two large cohort studies—the Whitehall Study of London Civil Servants and the British Regional Heart Study.

Link:Atrial Fibrillation as an Independent Risk Factor for Stroke: The Framingham Study, Philip A. Wolf, et al.

The impact of nonrheumatic atrial fibrillation, hypertension, coronary heart disease, and cardiac failure on stroke incidence was examined in 5,070 participants in the Framingham Study after 34 years of follow-up.

Link:Heart Disease and Stroke Statistics – 2016 Update: A Report from the American Heart Association, Mozaffarian D, et al.

Each year, the American Heart Association (AHA), in conjunction with the Centers for Disease Control and Prevention, the National Institutes of Health, and other government agencies, brings together the most up-to-date statistics related to heart disease, stroke, and other cardiovascular and metabolic diseases and presents them in its Heart Disease and Stroke Statistical Update.


PDF:2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Paulus Kirchhof, et al.

Guidelines and recommendations should help health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

Link:Guideline implementation: Exploring gap between evidence and practice in the CRUSADER quality improvement initiative, Blomkalns, A, et al.

Translating research results into routine clinical practice remains difficult. Guidelines, such as the 2002 American College of Cardiology/American Heart Association Guidelines for the Management of Patients with Unstable Angina and non-ST-segment elevation myocardial infarction, have been developed to provide a streamlined, evidence-based approach to patient care that is of high quality and is reproducible.

Link:2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, January CT, et al.

A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.


PDF:Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation, S. Ben Freedman, et al.

The general public has been conditioned over many years to accept aspirin as an effective, safe, and inexpensive remedy for heart attacks and for primary and secondary prevention of cardiovascular events.


Link:Current Status of Stroke Risk Stratification in Patients With Atrial Fibrillation, Robert G. Hart, et al.

Identifying independent risk factors for stroke in patients with atrial fibrillation is important for 2 main reasons: it sheds light on stroke pathogenesis associated with this common cardiac dysrhythmia, and it allows stratification of stroke risk for individual patients.

Link:Factors associated with undertreatment of atrial fibrillation in geriatric outpatients with Alzheimer disease, Tavassoli N, et al.

Treatment with a vitamin K antagonist is recommended in patients with atrial fibrillation in the presence of a high thromboembolic risk factor, or at least two moderate risk factors. In patients with a major contraindication, the vitamin K antagonist can be replaced by an antiplatelet agent. These recommendations are not systematically observed in patients with Alzheimer disease. The aim of our study was to determine the factors associated with undertreatment of AF in geriatric outpatients with AD.

Janssen's Commitment to Treating Cardiovascular Disease +

Our vision is to improve the lives of the millions of people with cardiovascular disease and diabetes, and to work tirelessly to eliminate these diseases. Every year 19 million people around the world die from cardiovascular and metabolic diseases. This tremendous global burden compels us to develop new therapies that will change the face of these diseases and, ultimately, eliminate them. We focus on finding and developing truly transformational therapies that target underlying disease pathways, important pathways, and novel mechanisms of action. We have a very successful track record demonstrated by the development and recent successful launches of our products for the treatment of patients suffering from thrombosis and type 2 diabetes. And we continue to seek and develop the next generation of transformational cardiovascular and metabolic therapies.

Focusing on the Most Devastating Diseases of Our Lifetime

We want to drive down the rates of cardiovascular and metabolic diseases with our science, innovation, and solutions. We are already transforming the treatment of type 2 diabetes and thrombosis with our products. And while these important products continue to change the way doctors are treating diabetes and thrombosis, we are also focused on finding the next wave of transformational treatments for cardiovascular and metabolic diseases that will prevent, intercept, and cure devastating diseases.